Aura Biosciences
AURA7.9903.50% ( +0.270 )
Aura Biosciences (AURA)
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables t...
- Open
- 7.810
- High
- 8.000
- Low
- 7.720
- Prev. Close
- 7.720
- Volume
- 538.28K
- Turnover
- 4.25M
- Avg Price
- 7.897
- Bid/Ask Ratio
- --
- Amplitude
- 3.63%
- 52wk High
- 9.535
- Volume Ratio
- 1.76
- Turnover Ratio
- 0.57%
Aura Biosciences Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$18.80135.29%
Forecast & RatingStrong buy
6analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Aug 5 at 04:23 PM
Aura Biosciences Expands Authorized Shares and Incentive Plan
- Quartr · Aug 5 at 09:36 AM
AURA: Shareholders approved all proposals, including a major increase in authorized common stock
- Market Beat · Aug 5 at 07:11 AM
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on Wednesday
- benzinga_article · Jul 24 at 07:04 AM
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Tip Ranks · Jul 22 at 03:55 PM
Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential
- PUBT · Jul 8 at 03:11 PM
Aura Biosciences director Jeremy Bender files initial beneficial ownership statement
